ArticleIJID regions2024
Seroprevalence patterns of viral hepatitis B, C, and E among internally displaced persons in Borno State, Nigeria.
Article in IJID regions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Objectives: Following the outbreak of hepatitis E in camps for internally displaced persons (IDPs) in Borno State in 2017, we assessed hepatitis B, C, and E biomarkers (hepatitis B surface antigen [HBsAg], anti-HBC, anti-hepatitis E virus [HEV] immunoglobulin [Ig] G, and anti-HEV IgM) among IDPs in three camps in Borno State, Nigeria, to determine seroprevalence rates in these understudied populations. Methods: A total of 454 IDPs, including pregnant women and breastfeeding mothers, were randomly selected, and their demographic, clinical, and epidemiological data were collected. Blood samples were tested for HBsAg and anti-hepatitis C virus (HCV) using rapid tests, anti-HEV IgM, and anti-HEV IgG using enzyme-linked immunosorbent assay. Results: The seroprevalences were 13.7% for HBsAg, 1.3% for anti-HCV, 41.9% for anti-HEV IgG, and 0% for anti-HEV IgM. There were differences between the camps depending on the displaced community. Common detection occurred in 0.2% for HBsAg/anti-HCV, 4.2% for HBsAg/anti-HEV IgG, and 0.7% for anti-HCV/anti-HEV IgG. In pregnant women, HBsAg/anti-HEV IgG co-detection rate was 28.6%, whereas HBsAg and anti-HEV IgG rates alone were 13.4% and 32.8%, respectively. Among breastfeeding mothers, 17.1%, 2.4%, and 36.6% were positive for HBsAg, anti-HCV, and anti-HEV IgG, respectively, whereas 2.2% of them were positive for both HBsAg and anti-HEV IgG. Conclusions: The prevalence of viral hepatitis biomarkers among the IDPs studied was higher than those reported in national figures and differed according to camps and population subgroups. There is a need for improved surveillance and access to testing for viral hepatitis biomarkers for the purpose of improved disease prevention and control in these medically underserved populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.